Gelfert Gloria G, Grittner Ulrike, Kuhnert Ronny, Scheidt-Nave Christa, Endres Matthias, Nave Alexander H
Center for Stroke Research Berlin (CSB), Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany; Department of Neurology with Experimental Neurology, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH) at Charité, Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
JACC Adv. 2025 Jul 23;4(8):102015. doi: 10.1016/j.jacadv.2025.102015.
BACKGROUND: Population-based data on the distribution of lipoprotein(a) (Lp[a]) within the German population are lacking. OBJECTIVES: The aim of the study was to determine the age- and sex-specific Lp(a) distribution in Germany and analyze its association with different types of cardiovascular disease (CVD). METHODS: We analyzed cross-sectional data from the German National Health Interview and Examination Survey 1998, a population-based study representing the German adult population's health status from 1997 to 1999. We examined serum Lp(a) according to demographics and investigated associations between Lp(a) and history of self-reported CVD. We tested Lp(a) in spline analysis on continuous scales and as dichotomous Lp(a) thresholds. RESULTS: In the German National Health Interview and Examination Survey 1998 (n = 6,657), median Lp(a) was 15.3 mg/dL (Q1-Q3: 5.6, 43.1). Lp(a) levels ≥50 mg/dL were present in 21.6%. Men had substantially higher median Lp(a) than women (22.1 mg/dL vs 10.3 mg/dL). Median Lp(a) levels were significantly higher in individuals with than without a history of atherosclerotic cardiovascular disease (ASCVD) but did not significantly differ between people with and without venous thrombosis. In logistic regression analysis with splines, higher Lp(a) levels were associated with a higher probability of a history of CVD. In logistic regression analyses, Lp(a) ≥50 mg/dL was associated with a history of ASCVD (OR: 1.36 [95% CI: 1.04-1.78]; P = 0.023). CONCLUSIONS: About 1 in 5 German individuals from a prestatin era population had Lp(a) levels ≥50 mg/dL. Higher levels were independently associated with ASCVD, but not with venous thrombosis. These findings provide a basis for future prospective studies to define the role of Lp(a) in CVD risk in the German population.
背景:德国人群中脂蛋白(a) [Lp(a)]分布的基于人群的数据尚缺。 目的:本研究旨在确定德国Lp(a)的年龄和性别特异性分布,并分析其与不同类型心血管疾病(CVD)的关联。 方法:我们分析了1998年德国国民健康访谈与检查调查的横断面数据,这是一项基于人群的研究,代表了1997年至1999年德国成年人群的健康状况。我们根据人口统计学特征检查血清Lp(a),并调查Lp(a)与自我报告的CVD病史之间的关联。我们在连续量表的样条分析中以及作为二分Lp(a)阈值来检测Lp(a)。 结果:在1998年德国国民健康访谈与检查调查(n = 6657)中,Lp(a)中位数为15.3 mg/dL(四分位数间距:5.6,43.1)。Lp(a)水平≥50 mg/dL的占21.6%。男性的Lp(a)中位数显著高于女性(22.1 mg/dL对10.3 mg/dL)。有动脉粥样硬化性心血管疾病(ASCVD)病史的个体的Lp(a)中位数水平显著高于无此病史者,但有和无静脉血栓形成者之间无显著差异。在样条逻辑回归分析中,较高的Lp(a)水平与CVD病史的较高概率相关。在逻辑回归分析中,Lp(a)≥50 mg/dL与ASCVD病史相关(比值比:1.36 [95%置信区间:1.04 - 1.78];P = 0.023)。 结论:在他汀类药物使用前时代的德国人群中,约五分之一的个体Lp(a)水平≥50 mg/dL。较高水平与ASCVD独立相关,但与静脉血栓形成无关。这些发现为未来前瞻性研究确定Lp(a)在德国人群CVD风险中的作用提供了依据。
Eur J Prev Cardiol. 2024-10-24
Eur J Prev Cardiol. 2025-7-14
Eur J Prev Cardiol. 2024-11-28
Cochrane Database Syst Rev. 2005-7-20
Curr Opin Lipidol. 2022-12-1
Atherosclerosis. 2022-5
Dtsch Arztebl Int. 2022-4-15